REG - Genflow Biosciences - Intellectual property Portfolio addition

Genflow BiosciencesAnnouncement

14/12/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221214:nRSN5772Ja&default-theme=true

RNS Number : 5772J  Genflow Biosciences PLC  14 December 2022

PRESS RELEASE

14 December 2022

 

Genflow Biosciences Plc

("Genflow" or "the Company")

 

Intellectual property (IP) Portfolio addition:

Patent submitted for transformational treatment of non-alcoholic fatty liver
disease (NAFLD)

Genflow (LSE: GENF), would like to announce that it has filed a new patent
application with the United States Patent and Trademark Office ("USPTO") that
relates to variants of Sirtuin-6 ("SIRT6"), and the gene variant's therapeutic
uses for the treatment of two disorders involving the liver: non-alcoholic
fatty liver disease ("NAFLD"), and non-alcoholic steatohepatitis ("NASH"), an
advanced form of NAFLD (the "Application").

Genflow holds the exclusive licence for this application through Genflow
Biosciences SRL (the Company's Belgian subsidiary).

NAFLD affects approximately 20% of the general population, meaning this is a
significant area for Genflow to be present in the research space with the
potential to change the lives of many disorder sufferers. The number of people
with NASH, I expected to rise dramatically in future years due to growing
obesity rates in developed nations.

In the past decade, large drugmakers including Allergan, Gilead and Novartis,
have spent billions of dollars acquiring or licensing medicines designed to
treat NASH.

Dr Eric Leire, Founder and CEO of Genflow, said: "I'm proud of the tremendous
progress Genflow has achieved in filing this new patent, and we look forward
to adding to the expanding body of knowledge about ageing, liver diseases and
bolstering our ever-growing patent portfolio."

IP Portfolio Update: SIRT6 Age-related cases

The international patent application for the use of SIRT6 in the treatment and
prevention of age-related diseases has received its first positive review from
the Patent Cooperation Treaty Examiner

The PCT Examiner has confirmed the novelty and inventiveness of Genflow's
filing which represents the first significant step on the path to the patent,
[for which Genflow already has an exclusive license,] being granted.

 

For further information please contact:

 Genflow Biosciences Plc
 Dr Eric Leire                       via Tancredi +44 203 434 2330

 Chief Executive
 Clear Capital Markets Ltd
 Corporate Broker                    +44 203 869 6086

 Jonathan Critchley                  +44 203 897 0981

 Keith Swann
 Tancredi Intelligent Communication

 Media Relations
 Salamander Davoudi                  +44 7957 549 906

 Helen Humphrey                      +44 7449 226 720

 Benedetta Negri da Oleggio          +44 7838 029 970

                                     genflowbio@tancredigroup.com

 

About Genflow

Genflow is a UK-based biotechnology company developing gene therapies designed
to target the ageing process and to reduce and delay the incidence of
age-related diseases. This will be done through novel therapeutics targeting
ageing in humans by using adeno-associated virus ("AAV") vectors to deliver
copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians
into cells.

Its mission is to increase understanding of the factors that control and
impact lifespan. Genflow researches develop and commercialise therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting ageing in dogs and humans. By treating ageing, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an ageing population.

To learn more visit www.genflowbio.com (http://www.genflowbio.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEADADFSNAFFA